Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Blue Sky Uranium Expands Drill Plan to Advance the Ivana Uranium-Vanadium Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
INmune Bio Inc
INMB
Healthcare
Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine...
if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:INMB)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(10)
•••
zardoz00
X
Post by
zardoz00
on Oct 24, 2024 5:56pm
INMB XPro™ Promotes Remyelination
https://us15.campaign-archive.com/?e=1c52cd69f7&u=4a549c7aea3073da1e942d0ce&id=9f6b228d23
(10)
•••
zardoz00
X
Post by
zardoz00
on Sep 30, 2024 8:13am
INMB completes phase two enrollment
https://us15.campaign-archive.com/?e=1c52cd69f7&u=4a549c7aea3073da1e942d0ce&id=5cb6aa3bde
(0)
•••
PressRelease
X
Post by
PressRelease
on May 09, 2024 4:05pm
New Press Release - INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
Company to Host Conference Call Today, May 9, at 4:30pm ET BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on May 07, 2024 8:00am
New Press Release - INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
Management to host conference call and webcast at 4:30 pm ET on that dayBoca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight...
read article.
(10)
•••
zardoz00
X
Post by
zardoz00
on Apr 30, 2024 8:13am
INMB Provides Update on Two Patients from the P1A with AD
Very good news! https://mail.google.com/mail/u/0/#inbox/FMfcgzGxStxShvDQGLmpNvjKCBszgRhR
(42)
•••
Teccing
X
Comment by
Teccing
on Apr 29, 2024 10:37am
RE:RE:RE:When the Price of (INMB) Talks, People Listen
Can e reach the market of ibrx? Maybe not this year, but certainly possible 2-3 years out.
(42)
•••
Teccing
X
Comment by
Teccing
on Apr 29, 2024 8:30am
RE:RE:When the Price of (INMB) Talks, People Listen
More encouraging new, with multiple fronts it's going to be a busy year.
(42)
•••
Teccing
X
Comment by
Teccing
on Apr 28, 2024 6:11pm
RE:When the Price of (INMB) Talks, People Listen
Lots of positive news looking forward, very low float, no debt, long runway. Like the risk reward.
(42)
•••
Teccing
X
Comment by
Teccing
on Feb 14, 2024 9:50pm
RE:FDA LIFT-OFF
Loving the future of inmb, enjoying the ride
(42)
•••
Teccing
X
Post by
Teccing
on Feb 06, 2024 9:25pm
FDA LIFT-OFF
Finally approved, should a exciting year a head, with multiple site trials coming do.
(42)
•••
Teccing
X
Post by
Teccing
on Jan 02, 2024 1:23pm
Prostate cancer
Praying for successful treatment, and hope for men who are battling this disease
(52)
•••
0checker
X
Comment by
0checker
on Sep 09, 2021 10:58pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Just the beginning
https://www.inmunebio.com/index.php/en/news-2/2021/468-muneioncnnouncesiomarkerataemonstratingtha20210825 " INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient
...more
(52)
•••
0checker
X
Comment by
0checker
on Sep 05, 2021 10:09am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Just the beginning
https://www.inmunebio.com/images/pdf/Presentation/2021/INMB_non-con_corp_August_1.pdf
(52)
•••
0checker
X
Comment by
0checker
on Sep 05, 2021 9:07am
RE:RE:RE:RE:RE:RE:RE:RE:RE:Just the beginning
https://twresearchgroup.com/2021/08/inkmune-induces-memory-like-nk-cells-this-is-a-very-big-deal/
(42)
•••
Teccing
X
Comment by
Teccing
on Sep 03, 2021 3:13pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:Just the beginning
I can't think of a more exciting investment then this one. Two great prospects, cancer cure, and game changing Alzhiemer' treatment.
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
How Web3 Will Fundamentally Reshape Finance
Largest integrated facility services provider in Canada releases financial results for Q1, 2025
Healthcare and Clinical Stage Drug Development Company Acquires NoBrainer Imaging Centers
This company is set to benefit from a change in Ontario legislation